Literature DB >> 26208034

Mesenchymal stem cell treatment in hyperoxia-induced lung injury in newborn rats.

Selvi Gülaşı1, Aytuğ Atıcı1, Şakir Necat Yılmaz2, Ayşe Polat3, Mustafa Yılmaz2, Melisa Türkoğlu Laçin4, Gülhan Örekici5, Yalçın Çelik1.   

Abstract

BACKGROUND: The aim of this study was to evaluate the effectiveness of tracheally delivered mesenchymal stem cells (MSC) on lung pathology in a hyperoxia-induced lung injury (HILI) model in neonatal rats.
METHODS: For the HILI model, rat pups were exposed to 85-95% oxygen during the first 10 days of life. Rats were divided into six groups: room-air normoxia (n = 11); room air, sham (n = 11); hyperoxia exposed with normal saline as placebo (n = 9); hyperoxia exposed with culture medium of MSC (n = 10); hyperoxia exposed with medium remaining after harvesting of MSC (n = 8); and hyperoxia exposed with MSC (n = 17). Pathologic changes, number and diameter of alveoli, α-smooth muscle actin (α-SMA) expression and localization of MSC in the lungs were assessed.
RESULTS: Number of alveoli increased and alveolar diameter decreased in the mesenchymal stem cell group so that there were no differences when compared with the normoxia group (P = 0.126 and P = 0.715, respectively). Expression of α-SMA decreased significantly in the mesenchymal stem cell group compared with the placebo group (P < 0001). Green fluorescent protein-positive cells were found in lung tissue from all rats given MSC. Some green fluorescent protein-positive MSC also expressed surfactant protein-C.
CONCLUSION: Mesenchymal stem cells became localized in damaged lung tissue, and recovery approximated the room air control.
© 2015 Japan Pediatric Society.

Entities:  

Keywords:  bronchopulmonary dysplasia; hyperoxia; lung injury; mesenchymal stem cell; newborn

Mesh:

Year:  2016        PMID: 26208034     DOI: 10.1111/ped.12764

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

Review 1.  Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns.

Authors:  Said A Omar; Amal Abdul-Hafez; Sherif Ibrahim; Natasha Pillai; Mohammed Abdulmageed; Ranga Prasanth Thiruvenkataramani; Tarek Mohamed; Burra V Madhukar; Bruce D Uhal
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

2.  Mesenchymal Stromal Cell Therapy in Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis of Preclinical Studies.

Authors:  Sajit Augustine; Marc T Avey; Brittany Harrison; Tiffany Locke; Mona Ghannad; David Moher; Bernard Thébaud
Journal:  Stem Cells Transl Med       Date:  2017-10-17       Impact factor: 6.940

3.  Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia.

Authors:  Sajit Augustine; Wei Cheng; Marc T Avey; Monica L Chan; Srinivasa Murthy Chitra Lingappa; Brian Hutton; Bernard Thébaud
Journal:  Stem Cells Transl Med       Date:  2019-11-20       Impact factor: 6.940

Review 4.  Mesenchymal Stromal/Stem Cells and Their Products as a Therapeutic Tool to Advance Lung Transplantation.

Authors:  Vitale Miceli; Alessandro Bertani
Journal:  Cells       Date:  2022-02-27       Impact factor: 6.600

Review 5.  The Potentials and Caveats of Mesenchymal Stromal Cell-Based Therapies in the Preterm Infant.

Authors:  Judith Gronbach; Tayyab Shahzad; Sarah Radajewski; Cho-Ming Chao; Saverio Bellusci; Rory E Morty; Tobias Reicherzer; Harald Ehrhardt
Journal:  Stem Cells Int       Date:  2018-04-08       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.